Minshu Yu

1.2k total citations
37 papers, 959 citations indexed

About

Minshu Yu is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Minshu Yu has authored 37 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Molecular Biology and 10 papers in Reproductive Medicine. Recurrent topics in Minshu Yu's work include PARP inhibition in cancer therapy (13 papers), Ovarian cancer diagnosis and treatment (10 papers) and Cancer-related Molecular Pathways (6 papers). Minshu Yu is often cited by papers focused on PARP inhibition in cancer therapy (13 papers), Ovarian cancer diagnosis and treatment (10 papers) and Cancer-related Molecular Pathways (6 papers). Minshu Yu collaborates with scholars based in United States, Norway and Italy. Minshu Yu's co-authors include Elizabeth G. Snyderwine, Elise C. Kohn, Liang Shan, Christina M. Annunziata, Lori M. Minasian, Bradford J. Wood, Seth M. Steinberg, Jung Min Lee, Nicolas Gordon and Nicole Houston and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Minshu Yu

37 papers receiving 939 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Minshu Yu United States	20	541	516	178	174	155	37	959
Verena Materna Germany	20	552 1.0×	632 1.2×	155 0.9×	109 0.6×	220 1.4×	33	1.1k
R. Gätje Germany	16	507 0.9×	291 0.6×	106 0.6×	93 0.5×	206 1.3×	24	865
Martina L. Skrede Norway	16	520 1.0×	241 0.5×	93 0.5×	172 1.0×	247 1.6×	22	1.0k
H. Meden Germany	19	355 0.7×	492 1.0×	288 1.6×	118 0.7×	146 0.9×	68	1.0k
Maria Grazia Prisco Italy	16	310 0.6×	316 0.6×	159 0.9×	131 0.8×	117 0.8×	22	761
Xiangbing Meng United States	24	912 1.7×	439 0.9×	96 0.5×	152 0.9×	225 1.5×	58	1.3k
Rohini Roy United States	7	870 1.6×	434 0.8×	105 0.6×	441 2.5×	239 1.5×	10	1.2k
Laura M. Handel United States	11	444 0.8×	335 0.6×	208 1.2×	84 0.5×	100 0.6×	13	812
Letícia Batista Azevedo Rangel Brazil	14	568 1.0×	284 0.6×	77 0.4×	111 0.6×	280 1.8×	39	1.1k
M. J. Birrer United States	14	947 1.8×	537 1.0×	229 1.3×	191 1.1×	337 2.2×	24	1.5k

Countries citing papers authored by Minshu Yu

Since Specialization

Citations

This map shows the geographic impact of Minshu Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minshu Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minshu Yu more than expected).

Fields of papers citing papers by Minshu Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minshu Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minshu Yu. The network helps show where Minshu Yu may publish in the future.

Co-authorship network of co-authors of Minshu Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Minshu Yu. A scholar is included among the top collaborators of Minshu Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minshu Yu. Minshu Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Jungmin, Christina M. Annunziata, John L. Hays, et al.. (2020). Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. Gynecologic Oncology. 159(1). 88–94. 24 indexed citations

Lee, Jung Min, Cody J. Peer, Minshu Yu, et al.. (2016). Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clinical Cancer Research. 23(6). 1397–1406. 47 indexed citations

Lee, Jungmin, Jane B. Trepel, Peter L. Choyke, et al.. (2015). CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Frontiers in Oncology. 5. 123–123. 20 indexed citations

Lee, Jung Min, Nicolas Gordon, Jane B. Trepel, et al.. (2015). Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer. Journal of Translational Medicine. 13(1). 239–239. 13 indexed citations

Lee, Jung Min, John L. Hays, Christina M. Annunziata, et al.. (2014). Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses. JNCI Journal of the National Cancer Institute. 106(6). dju089–dju089. 145 indexed citations

Lee, Jung Min, John L. Hays, Anne M. Noonan, et al.. (2012). Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials. Cancer. 119(7). 1357–1364. 23 indexed citations

Yu, Minshu, Amanda J. Walker, Geoffrey Kim, et al.. (2012). L‐asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. Journal of Cellular and Molecular Medicine. 16(10). 2369–2378. 52 indexed citations

Kim, Geoffrey, Ben Davidson, Junbai Wang, et al.. (2011). Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer. 118(6). 1543–1553. 20 indexed citations

Annunziata, Christina M., Amanda J. Walker, Lori M. Minasian, et al.. (2010). Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2. Clinical Cancer Research. 16(2). 664–672. 69 indexed citations

10.

Winters, Mary, et al.. (2007). Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. PROTEOMICS. 7(22). 4066–4068. 17 indexed citations

11.

Shan, Liang, et al.. (2005). Gene expression profiling in the mammary gland of rats treated with 7,12‐dimethylbenz[a]anthracene. International Journal of Cancer. 118(1). 17–24. 29 indexed citations

12.

Shan, Liang, et al.. (2005). Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5- b ]pyridine. Carcinogenesis. 26(4). 763–769. 24 indexed citations

13.

Shan, Liang, Minshu Yu, & Elizabeth G. Snyderwine. (2004). Gene expression profiling of chemically induced rat mammary gland cancer. Carcinogenesis. 26(2). 503–509. 20 indexed citations

14.

Shan, Liang, Minshu Yu, Bradly D. Clark, & Elizabeth G. Snyderwine. (2004). Possible role of Stat5a in rat mammary gland carcinogenesis. Breast Cancer Research and Treatment. 88(3). 263–272. 25 indexed citations

15.

Shan, Liang, Minshu Yu, Herman A.J. Schut, & Elizabeth G. Snyderwine. (2004). Susceptibility of Rats to Mammary Gland Carcinogenesis by the Food-Derived Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP) Varies with Age and Is Associated with the Induction of Differential Gene Expression. American Journal Of Pathology. 165(1). 191–202. 22 indexed citations

16.

Yu, Minshu, et al.. (2003). Allelic imbalance and altered expression of genes in chromosome 2q11–2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Oncogene. 22(8). 1253–1260. 17 indexed citations

17.

Snyderwine, Elizabeth G., et al.. (2002). Mammary gland carcinogenesis by food-derived heterocyclic amines and studies on the mechanisms of carcinogenesis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutation research. Fundamental and molecular mechanisms of mutagenesis. 506-507. 145–152. 43 indexed citations

18.

Yu, Minshu, Doug‐Young Ryu, & Elizabeth G. Snyderwine. (2000). Genomic imbalance in rat mammary gland carcinomas induced by 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine. Molecular Carcinogenesis. 27(2). 76–83. 22 indexed citations

19.

Yu, Minshu, Suzanne U. Emerson, Paul J. Côté, Max Shapiro, & Robert H. Purcell. (1998). The GDPAL region of the pre-s1 envelope protein is important for morphogenesis of woodchuck hepatitis virus. Hepatology. 27(5). 1408–1414. 3 indexed citations

20.

Gervasoni, James E., Taub Rn, Minshu Yu, et al.. (1992). Homogeneously staining region in anthracycline-resistant HL-60/AR cells not associated with MDR1 amplification.. PubMed. 52(19). 5244–9. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact